# DESCRIPTION

## FIELD

- define field of disclosure

## INTRODUCTION

- motivate need for alternative methods

## SUMMARY

- introduce gRNA molecule
- describe DNA targeting system
- summarize aspects of disclosure
- outline embodiments of disclosure

## DETAILED DESCRIPTION

- introduce DNA targeting systems
- motivate CRISPR/Cas9 system
- describe CRISPR/Cas9-based transcriptional activators
- application of Pax7 activation

### 1. Definitions

- define technical terms
- introduce open-ended transitional phrases
- explain numeric ranges
- define "about" or "approximately"
- introduce adeno-associated virus (AAV)
- define amino acid
- explain binding region
- introduce CRISPRs
- define coding sequence
- explain complement or complementary
- define control, reference level, and reference
- define operably linked
- define partially-functional protein
- define peptide and polypeptide
- define primary, secondary, tertiary, and quaternary structure
- define motif
- define premature stop codon
- define promoter
- define recombinant
- define sample
- define spacers
- define subject
- define substantially identical
- define transcription activator-like effector (TALE)
- define target gene and target region
- define transgene, treatment, variant, and vector

### 2. Pax7

- define Pax7

### 3. CRISPR/Cas-Based Gene Editing System

- introduce CRISPR/Cas-based gene editing system
- describe CRISPR system
- explain Type II effector system
- detail Cas9 protein function
- describe tracrRNA function
- explain target recognition and cleavage
- discuss PAM requirements
- introduce engineered CRISPR/Cas9-based systems
- describe Cas9 fusion protein
- explain gRNA function
- discuss target gene options
- describe Cas protein options
- explain Cas12 protein function
- discuss PAM sequence recognition
- introduce inactivated Cas9 protein (iCas9)
- describe dCas9 mutations
- explain synthetic polynucleotide options
- introduce fusion protein options
- describe transcription activation and repression activities
- describe CRISPR/Cas-based gene editing system
- introduce second polypeptide domain activities
- motivate transcription release factor activity
- motivate histone modification activity
- motivate nuclease activity
- motivate nucleic acid association activity
- motivate methylase activity
- motivate demethylase activity
- introduce gRNA molecule
- describe gRNA targeting portion and scaffold
- introduce DNA targeting system
- describe DNA targeting composition

### 4. Genetic Constructs

- describe genetic construct components
- detail promoter and polynucleotide encoding
- outline delivery vehicle options

### 5. Pharmaceutical Compositions

- formulate genetic constructs into pharmaceutical compositions
- describe additives for isotonicity and stabilizers
- outline pharmaceutically acceptable excipients and transfection facilitating agents

### 6. Administration

- administer DNA targeting systems or pharmaceutical compositions
- detail routes of administration
- describe delivery technologies
- outline specific administration methods

### 7. Methods

- describe methods of activating endogenous myogenic transcription factor Pax7
- outline methods of differentiating stem cells and treating subjects

### 8. Examples

- introduce example 1
- describe materials and methods for example 1
- outline lentiviral production for example 1
- detail cell culture and differentiation for example 1
- describe fluorescence activated cell sorting and expansion for example 1
- outline flow cytometry analysis for example 1
- describe cell transplantation into immunodeficient mice for example 1
- detail immunofluorescence staining of cultured cells and tissue sections for example 1
- introduce example 2
- describe developing conditions for VP64-dCas9-VP64-mediated endogenous Pax7 activation in hPSCs
- introduce example 3
- describe VP64-dCas9-VP64-mediated differentiation of hPSCs into myogenic progenitor cells
- introduce example 4
- characterize myogenic progenitor cells derived from endogenous or exogenous PAX7 expression
- introduce PAX7 mRNA levels assessment
- describe qRT-PCR detection of PAX7 isoforms
- motivate downstream myogenic regulatory factors detection
- summarize human satellite cells co-expression analysis
- introduce Example 5: transplantation of VP64-dCas9-VP64-generated myogenic progenitors
- describe in vivo regenerative potential assessment
- introduce Example 6: sustained endogenous PAX7 expression after multiple passages
- describe PAX7 protein expression quantification
- introduce Example 7: sustained PAX7 expression and stable chromatin remodeling
- describe ChIP-qPCR analysis of histone modifications
- introduce Example 8: identification of endogenous vs. exogenous PAX7-induced global transcriptional changes
- summarize RNA-seq analysis and GO term analysis

### Discussion

- introduce CRISPR/Cas9-based transcriptional activators
- motivate alternative to transgene overexpression model
- describe minimal small molecule differentiation protocol
- demonstrate targeted activation of endogenous PAX7 gene
- compare with PAX7 cDNA overexpression
- discuss differential RNA cleavage and polyadenylation
- analyze RNA-seq data for myogenic function
- motivate integration-free reprogramming
- discuss CRISPR genome engineering toolbox
- introduce novel method for differentiation and expansion
- provide general concept of the present disclosure

